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Abstract
Background: It is a priority to achieve smoking cessation in diabetic smokers, given that this is a group of patients
with elevated cardiovascular risk. Furthermore, tobacco has a multiplying effect on micro and macro vascular
complications. Smoking abstinence rates increase as the intensity of the intervention, length of the intervention
and number and diversity of contacts with the healthcare professional during the intervention increases. However,
there are few published studies about smoking cessation in diabetics in primary care, a level of healthcare that
plays an essential role in these patients. Therefore, the aim of the present study is to evaluate the effectiveness of
an intensive smoking cessation intervention in diabetic patients in primary care.
Methods/Design: Cluster randomized trial, controlled and multicentric. Randomization unit: Primary Care Team.
Study population: 546 diabetic smokers older than 14 years of age whose disease is controlled by one of the
primary care teams in the study. Outcome Measures: Continuous tobacco abstinence (a person who has not
smoked for at least six months and with a CO level of less than 6 ppm measured by a cooximeter) , evolution in
the Prochaska and DiClemente’s Transtheoretical Model of Change, number of cigarettes/day, length of the visit.
Point of assessment: one- year post- inclusion in the study. Intervention: Brief motivational interview for diabetic
smokers at the pre-contemplation and contemplation stage, intensive motivational interview with
pharmacotherapy for diabetic smokers in the preparation-action stage and reinforcing intevention in the
maintenance stage. Statistical Analysis: A descriptive analysis of all variables will be done, as well as a multilevel
logistic regression and a Poisson regression. All analyses will be done with an intention to treatment basis and will
be fitted for potential confounding factors and variables of clinical importance. Statistical packages: SPSS15,
STATA10 y HLM6.
Discussion: The present study will try to describe the profile of a diabetic smoker who receives the most benefit
from an intensive intervention in primary care. The results will be useful for primary care professionals in their usual
clinical practice.
Trial Registration: Clinical Trials.gov Identifier: NCT00954967
Background
It is known that tobacco is the principal isolated cause
of avoidable morbimortality in developed countries. Half
of these deaths are premature, provoking a loss of 5.5
million potential years of life annually, 3.3 million in
men and 2.2 million in women [1]. Smoking related
diseases are the cause of death in 50% of smokers [2].
The most recent mortality data indicate that tobacco
causes 54,233 deaths annually in Spain [3]. In a study
about mortality attributable to the active consumption
of tobacco in Spain from 1978 to 1992, it was observed
that 1 out of every 3 deaths was in a person younger
than 65 years of age who had a high life expectancy [3].
The morbimortality observed in diabetics is related to
macro and microvascular complications, and tobacco
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has a multiplying effect on these vascular complications.
Furthermore, it has been demonstrated that tobacco
consumption is associated with mortality due to isque-
mic heart disease in diabetic patients [4]. A number of
studies have found evidence relating tobacco consump-
tion to the development of nephropathies in type 1 and
2 diabetes mellitus [4]. It has also been shown that the
tobacco consumption is a risk factor for the develop-
ment and progression of diabetic neuropathies [5].
According to recommendations in national and inter-
national guidelines, achieving smoking cessation is a
priority in diabetic smokers, given that this group has
two to four times more cardiovascular risk when com-
pared to the general population [6-8].
In the present study, Prochaska and DiClemente’s
Transtheoretical Model of Change will be used. This
model describes a series of successive stages (precon-
templation, contemplation, preparation, action and
maintenance) that signal a different type of intervention
depending on the person’s stage. Despite the discre-
pency regarding the utility of this model in smoking ces-
sation [9,10], the majority of clinical guidelines in
primary care (PC) consider useful because it helps to
make decisions regarding treatment. Furthermore, it
allows the professional to gauge the evolution of the
patient’s attitude towards smoking cessation.
Although there are differences between type 1 and
type 2 diabetes, previous studies show that the majority
of diabetic smokers are in the pre-contempative stage of
Prochaska and DiClemente’s model. In a study by Rug-
giero et al, people that received some type of smoking
cessation advice made more progress in the process of
smoking cessation [11].
Cooximeters have been used to demonstrate contin-
ued smoking abstinence. Consensus documents have
recommended this technique, concluding that it is use-
ful in diagnosing and in aiding with the process of
smoking cessation [12].
It its known that minimum advice for smoking cessa-
tion in the general population achieves a mean 5%
smoking cessation in one year [13] while interventions
with intensive follow-ups can achieve a mean of 20%
smoking cessation [14]. In general, abstinence rates
increase with the intensity of the intervention, the time
used in the intervention and the number and diversity
of contacts with the healthcare professional, including
follow-up visits [4,15]. Health interventions in tobacco
consumption can be considered to have a low cost in
relation to the quality and years of life gained. From a
public health point of view, the obtained results possibly
constitute the most cost efficient process to improve the
health of the population [14,16].
Integrating pharmocological treatments that have been
shown to be efficient in meta analyses and systematic
revisions (nictone substitutes, Bupropion and Vareni-
cline) has also been shown to be useful [17-19].The effi-
cacy and effectiveness of interventions using
recommendations similar to the present study have also
been studied in PC, such as the ISTAPS study [20].
Due to the difficulty of an interventon in a population
as advised and resistant to change as diabetic smokers
[21,12], advancing in the stages of change of Prochaska
and DiClemente’s model, as well as decreasing the num-
ber of cigarettes, are also seen as important in addition
to smoking abstinence [21,12].Therefore, they will also
be objectives in the current study.
Various studies have shown that the more intense an
intervention, the better the results obtained. In Persson
et al [22], a Swedish study carried out in 412 diabetic
smokers in PC, subjects in the intervention group
received smoking cessation advice and were followed by
telephone or in group sessions, while subjects in the
control group were mailed smoking cessation advice.
The one-year abstinence rate was 20% in the interven-
tion group and 7% in the control group. Furthermore,
within the intervention group, 40% of those who partici-
pated in the group therapy quit smoking, compared to
14% in of those who were followed by telephone. In
Canga et al [23], a randomized clinical trial that evalu-
ated the effectiveness of an smoking cessation interven-
tion using intensive follow-up in diabetic smokers, the
six-month continued abstience rate was 17% in the inte-
vention group and 2.3% in the control group. In inter-
vention group subjects that did not quit smoking, the
number of cigarettes smoked decreased. It was con-
cluded that a structured intervention increases smoking
cessation in diabetic smokers.
Another study in diabetic smokers carried out in Min-
neapolis, Minnesota [24] concluded that programs for
diabetes education should include intensive interven-
tions for smoking cessation because they increase the
efficacy of advice and do not have a negative effect on
the metabolic control of diabetes.
There are only a few studies published about smok-
ing cessation in diabetic smokers in PC, despite the
fact that most diabetic patients visit their PC physician
various times per year for routine check ups. Accord-
ing to the World Health Organization [25], diabetes
control and prevention activities should be based in
PC. This suggests that PC is the ideal environment for
intensive interventions in smoking cessation in diabetic
smokers.
For all of the abovementioned reasons, the effective-
ness of an intensive smoking cessation intervention in
diabetic smokers in PC, based on the Prochaska and
DiClemente Transtheoretical Model of Change and
motivational interview techniques, will be evaluated in
the present study.
Roig et al. BMC Public Health 2010, 10:58
http://www.biomedcentral.com/1471-2458/10/58
Page 2 of 8
Hypothesis
The present smoking cessation intervention in diabetic
patients in PC, which uses an intensive strategy that is
motivational, individualized, structured and adapted
accoding to the Prochaska and DiClemente’s Trans-
theoretical Model of Change, will cause a difference in
continued abstinence of 12% between patients that
receive the intervention versus those who do not. This
takes into consideration the fact that smoking cessation
in the general population is 5% with minimum advice
[13] and 20% with intensive advice [14].
Objectives
Principal objective
To evaluate the effectiveness of an intensive intervention
to obtain continued smoking abstinence in diabetic
patients in PC.
Secondary objectives
1. To study the effectiveness of an intensive smoking
cessation intervention in the evolution of Prochaska and
DiClemente’s Transtheoretical Model of Change in dia-
betic patients in PC.
2. To study the effectiveness of an intensive smoking
cessation intervention in the evolution of tobacco con-
sumption in diabetic patients in PC.
3. To quantify the time spent on the intensive smok-
ing cessation intervention versus usual clincial practice
in PC.
Methods/Design
Design
Cluster randomized trial, controlled and multicentric.
Randomization unit: Primary Care Team (PCT).
Setting
43 PCTs from the province of Barcelona that provide
health coverage to urban, semirural and rural
populations.
Study population
Type 1 and 2 diabetic smokers older than 14 years of
age that receive routine diabetes care in the participating
PCT. An active smoker is defined as a patient that
responds affirmatively to the following questions: 1. Do
you smoke currently? 2. Have you smoked more than
100 cigarettes in your lifetime? 3. Have you smoked any
tobacco product in the last seven days? [26,27].
Exclusion criteria
Patients with communication difficulties (cognitive or sen-
sory deterioration, language barrier); patients that have
not had check ups for their diabetes in the PCT for more
than one year; patients with terminal illnesses, serious psy-
chologial illnesses, active addictions to other psychoactive
substances; patients that are already in the process of quit-
ting smoking; patients that live more than six months
outside of the territory assigned to the PCT; and patients
who do not consent to participate in the study.
Withdrawl criteria
Any event that may lead to a situation that discourages
the intervention or that may prevent communication
with the healthcare professional.
Sample size calculation
The sample size has been calcuated by multipying the
size of a randomized simple design by the design effect.
In the simple randomized design, considering an alpha
error of 0.05 a beta error of 0.20 in a bilateral contrast,
and given that 15% of diabetics are smokers, 124 sub-
jects were needed in each study group in order to deter-
mine a difference in continued abstinence of greater
than or equal to 12% between study groups. A contin-
ued abstinence of 5% was assumed for the non interven-
tion group, and a potential loss of follow-up of 20% was
estimated.
Using an intracluster correlation coefficient of 0.05
[28-30], and based on an average of 25 diabetic smokers
per PCT, the design effect is 2.2. Therefore, 546 diabetic
smokers and 22 PCT were needed. The sample size was
calculated using the Granmo 5.2 program for Windows.
Data Collection
Dependent Variables
• Continued abstinence (yes, no) is defined as at least six
months without smoking and a CO breath level of <6
ppm, measured by a cooximeter in standard conditions.
• Stage change in Prochaska and DiClemente’s Trans-
theoretical Model of Change (advance, maintained,
backwards, relapse).
• Number of cigarettes per day, reported by the
patient.
• Total time (in minutes) spent on the intervention.
Independent Variables
• Variables related to the patient (information obtained
through an individualized interview):
- Administrative: PCT, PC professional, data collec-
tion date, patient code.
- Sociodemographics: date of birth, sex, level of
education.
- Anthropometric: weight, height.
• Related to diabetes: type, year of diagnosis, type of
treatment, presence of complications related to diabetes
(peripheral arterial disease, ischemic heart disease, reti-
nopathy, neuropathy, nephopathy).
• Related to associated pathologies: COPD, cerebro-
vascular accident, isquemic heart disease, hypertension,
hypercholesterolemia.
• Variables related to tobacco consumption: age at
initiation of habit, number of cigarettes per day, nicotine
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dependence (Fagerström test), motivation to quit (Rich-
mond test), number of previous attempts to quit for at
least 24 hours, smoking cessation treatment with medi-
ciations, maximum time of abstinence, phase of the
patient according to Prochaska and DiClemente’s model
(pre-contemplation, contemplation, preparation-action),
tobacco in usual environment (family, partner, friends,
coworkers, classmates), perceived grade of harmfulness
of tobacco on diabetes, point prevalence abstinence
(smoking abstinence at the time of the visit and with a
CO level of less than 6 ppm), length of abstinence.
• Variables related to the intervention: attendance of
intervention visit, date of intervention visit, date of D
day, time spent on intervention visit, medication used
for smoking cessation, relapse, reason for relapse, CO
level in breath, observations.
• Variables related to the one-year follow-up visit:
attendance to follow-up visit, date of follow-up visit,
smoking status, number of cigarettes per day, length of
abstinence, phase of the patient according to Prochaska
and DiClemente’s model (pre-contemplation, contem-
plation, preparation-action), CO level in breath,
observations.
• Variables related to the PCT: years the PCT has
been operating, assigned population, mean age of
assigned population, whether or not it is a teaching cen-
ter for residents, number of doctors, number of nurses,
number of social workers, other specializations, number
of centers.
Description of the Study
The phases of the study are:
Phase 1
Recruitment of the PCT: The project was presented to
all of the potential PCTs in order to recruit health pro-
fessional that were interested in participating. Both doc-
tors and nurses were allowed participate. Those who
wanted to collaborate signed a comittment form.
Phase 2
Forming the study groups (Intervention group (IG) and
non intervention group (NIG)) and training the health
professionals.
- The unit of randomization was the center. The
centers were assigned to either the IG o the NIG by
simple randomization, with a ratio of 1 to 1. The
system of randomization was centralized and
computerized.
- The professionals in the IG received a specific
training program that consists of a motivational
interview workshop and a pharmocological treat-
ment workshop specialized for smoking cessation.
Both workshops were geared towards diabetic smo-
kers and were taught by experts. The professionals
also received training in how to use the electronic
data collection system and in the dynamics of the
follow-up visits according the Prochaska and DiCle-
mente’s Transtheoretical Model of Change. The pro-
fessionals in the NIG attened practical training
session that covered the methodology of the study
and how to use the electronic data collection system.
Phase 3
Recruitment of the patients and initial categorization in
IG and NIG (currently the study is in this phase):
- Selection of patients: Patients were recruited as
they visited the PCT. If in the month prior to clos-
ing the patient recruitment phase a professional had
not recruited the number of patients required, a list
of diabetic smokers could be obtained and the
necessary number was selected by simple randomi-
zation. The professional called the selected patients
to make an appointment. According to a previous
estimation and taking into consideration the sample
size, each professional had to recruit five patients.
The form of recruitment, as well as the number of
patients to be recruited by each professional, was
considered feasible for professionals in routine clini-
cal practice.
- Inclusion of patients: If a patient met the inclusion
criteria, the doctor or nurse explained the study to
the patient and solicited the patient’s participation. If
the subject agreed, he or she received information
about the study and signed a consent form. If the
subject did not wish to participate, the motives were
documented.
- Initial categorization of patients: In the first con-
tact with the patient, the following variables were
collected using an individualized interview.
- Independent: administrative, sociodemographic,
anthropometric, those related with diabetes,
associated pathologies and those related to the
smoking habit
- Dependent: length of visit
- All of the data is being registered in the electronic
data collection system which includes measures to
assure consistency and quality control.
- Pilot program: A pilot program will be carried out
in subjects that will be excluded from the study so
as not to affect the final results. The pilot program
aims to evaluate: the process of inclusion of subjects,
data collection using the electronic system and the
difficulties encountered in the intervention and in
the established circuits.
Phase 4
Intervention (only in IG): An intensive, individualized
intervention using the motivational interview, conduct
therapies and medications, adapted according to the
stage of change of the patient, will be used. The number
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of visits will depend on the stage that the patient is in
(five for pre-contemplation, seven for contemplation
and eight for preparation-action). Patients can move for-
ward and backward in their stage over the course of the
study, and the study will adapt to these changes. The
phases of the intervention will be detailed in the IG
algorithm (see Figure 1).The variables to be collected
are specified in the electronic data collection system.
The patients of the NIG group will receive the usual
care in PC, and at the end of the study, the NIG profes-
sionals will also be trained in the motivational interview
and in pharmocological treatments.
Phase 5
Final categorization (in IG and NIG): The dependent
variables will be collected in all subjects at one-year
post- inclusion. The motives for withdrawl and loss of
follow-up from the study will be recorded and a flow
chart of participants will be created over the course of
the study.
Phase 6
End of data collection: Data collection will be concluded
after carrying out the final patient categorization.
Because of the periodic monitoring of the data in the
electonic data collection system, incoherencies will have
been located and corrected.
Phase 7
Data analysis and diffusion of results: The collected
data will be analyzed, the final report will be elabo-
rated and the results will be diffused in various scienti-
fic outlets.
Figure 1 ITADI Intervention group study algorithm.
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Statistical analysis
Data will be analyzed in concordance with the Consort
Cluster guide [31], and all analyses will be done on an
intention to treat basis. A descriptive analysis and an
analysis of baseline comparability between the study
groups will be performed for the variables studied. A
T-student test or a U Mann Whitey will be used to
compare means with two categories, an ANOVA test
will be done to compare means with two or more cate-
gories, and a Chi- squared test or a Chi -squared ten-
dency test will be done to compare categorical
variables. A multilevel logistic regression and a Poisson
regression will be done to evaluate the association
between each of the dependent variables and the inde-
pendent variables that have resulted statistically signifi-
cant in the bivariate analisis. All analisis will be
adjusted for potential confounding factors and for vari-
ables with clinical relevance. All tests will be done
with a 95% bilateral confidence interval. SPSS 15,
STATA 10 and HLM6 will be used.
Quality Control
Several procedures were employed to ensure the quality
of the study data, thus maximizing the validity and relia-
bility of the program delivery and outcome assessments.
They were:
• An eight -hour training the professionals who par-
ticipated in the study in motivational interviewing,
pharmocological treatment of smoking, and use of
the electronic data collection system.
• Use of an electronic data collection system with a
system of warnings and intenal coherency noms.
• A full time person contracted to provide technical
and methodological support to the study
participants.
• Regular meetings and mailings between members
of the study group and all participating centers.
Ethical Aspects
In the first contact with the patient, he or she will be
given information about the study and will sign an
informed consent form if he or she wishes to partici-
pate. The informed consent will detail the ethical condi-
tions and the paricipant’s right to intimacy, anonymity,
confidentiality, withdrawl and information. The
researchers also commit to respect the norms of good
clinical practice, as well as the requirements of the Hel-
sinki Declaration. The protocol has been evaluated and
approved by the Ethical Committee of Scientific Reseach
and the Jordi Gol Center for Investigation in Primary
Care. Confidentiality of data: Only the investigators and
monitors/auditors of the study will have access to the
data of the subjects who agreed to participate.
Discussion
Although there are studies that use intensive interven-
tions in smoking cessation such as the ISTAPS study
[20], the majority are directed towards the general popu-
lation. The challenge of the present study is to exclu-
sively direct the intervention towards diabetic smokers
in PC. The fact that these type of patients are resistant
to change should not be an obstacle, as it is a priority to
address the topic of smoking when dealing with patients
with an elevated cardiovascular risk. Furthermore, it
should be kept in mind that the intention of this inter-
vention is not only to achieve continued smoking absti-
nence, but also to achieve partial goals, such as
advancing in the stages of change of Prochaska and
DiClemente and the reduction of the number of cigar-
ettes smoked per day. These partial goals can motivate a
healthcare professional who has tried unsuccessfully on
several occasions to get his or her patient to quit smok-
ing, to continue working towards progress.
One of the stengths of the ITADI study is the popula-
tion of the study, diabetic patients that attend PC.
Another strength is the design of the study, which is
pragmatic in terms of time and material resources
needed. If the hypothesis of the present study is con-
fimed, it could be incorporated into current PC clinical
practice guidelines. The large number of healthcare pro-
fessionals and patients involved in the present study is
another strength, as it reinforces the external validity of
the data.
The randomization has been done by PCT and not by
patient, so as to avoid the unethical situation in which a
healthcare professional would feel obligated to use the
motivational interview and pharmocotherapy in only
some of his or her patients. This will also prevent con-
tamination between healthcare professionals of the same
center. Although the unit of randomization is the center,
the intervention is given at the individual level and the
outcomes are also measured at this level. The estimation
of the design effect will be taken into account in all of
the main analyses.
The motivational interview techiques require personal
communication and empathy from the part of the
healthcare professional towards his or her patient. The
training sessions are one full day, although it is known
that the more training the professional has in motiva-
tional interviewing, the more he or she is able to apply
the learned skills [32].
Cooximetry is a technically simple and affordable
method to apply in PC, as well as valid and useful [12];
however, it has some management limitations. In order
to overcome these limitations, the healthcare profes-
sionals of both study groups will be trained in how to
use cooximeters. Furthermore, an instruction manual
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and audiovisual guide will be designed on how to use
the cooximeters. The cooximetry measures will be taken
in the afternoon in homogenous and standarized
conditions.
Finally, the current study will try to describe the pro-
file of a diabetic smoker who receives the most benefit
from an intensive smoking cessation intervention in PC.
The goal is to use the results of the study as a founda-
tion for a protocolized intervention in PC guidelines for
diabetes
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